|1.||Burnie, James: 3 articles (05/2006 - 07/2003)|
|2.||Matthews, Ruth: 2 articles (05/2006 - 02/2004)|
|3.||Matthews, Ruth C: 2 articles (01/2005 - 07/2003)|
|4.||Tsoulas, Christos: 1 article (08/2013)|
|5.||Kerl, Kornelius: 1 article (08/2013)|
|6.||Groll, Andreas H: 1 article (08/2013)|
|7.||Tragiannidis, Athanasios: 1 article (08/2013)|
|8.||Posteraro, Brunella: 1 article (01/2013)|
|9.||Martini, Cecilia: 1 article (01/2013)|
|10.||Bugli, Francesca: 1 article (01/2013)|
07/01/2003 - "min/ml. Mycograb (2 mg/kg) alone produced significant improvement in murine candidiasis caused by each species: (i). "
02/01/2004 - "The first recombinant antibody fragment, Mycograb (Neu Tec Pharma plc), against Candida HSP90 is now in clinical trials in patients with disseminated candidiasis in Europe and the US. "
01/01/2013 - "First data on Mycograb C28Y variant indicate that this monoclonal antibody lacked efficacy in a murine candidiasis model. "
06/01/2005 - "The concepts behind a Phase II pivotal study, where Mycograb or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed."
11/01/2009 - "To review the use of efungumab as an adjunctive agent in the treatment of invasive candidiasis (IC) and to provide guidance on formulary placement. "
11/01/2009 - "Efungumab: a novel agent in the treatment of invasive candidiasis."
10/15/2006 - "Mycograb for the treatment of invasive candidiasis."
05/15/2006 - "Mycograb plus lipid-associated amphotericin B produced significant clinical and culture-confirmed improvement in outcome for patients with invasive candidiasis."
05/15/2006 - "A double-blind, randomized study was conducted to determine whether lipid-associated amphotericin B plus Mycograb was superior to amphotericin B plus placebo in patients with culture-confirmed invasive candidiasis. "
07/01/2003 - "Only by combining Mycograb with AMB was complete resolution of infection achieved for C. "
07/01/2011 - "Quantitative cultures of kidneys, livers, and spleens of neutropenic mice with systemic Candida albicans infections were used to assess the in vivo interaction between 1.4 mg/kg of body weight/day of DAMB and 0.15, 1.5, and 15 mg/kg/day of the Mycograb C28Y variant after 1, 3, and 5 days of therapy. "
01/01/2005 - "These data suggest that the combination of amphotericin B and Mycograb would be worth exploring in the treatment of infection due to C. "
08/01/2013 - "The thorough understanding of the available antifungal agents in combination with the increasing knowledge of the mechanisms that underlie the pathogenesis of Candida infections and the development of newer approaches such as efungumab and immunotherapy with adjunctive cytokines may improve the prognosis of patients with life-threatening invasive Candida infections."
|1.||Amphotericin B (Amphotericin)
|2.||liposomal amphotericin B
|3.||Heat-Shock Proteins (Heat-Shock Protein)